New stroke medicine SP-8203 with clot-busting therapy
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a new medicine called SP-8203 added to standard clot-busting treatment for people having a moderate to severe stroke. The goal is to see if it helps improve recovery and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your stroke must have caused at least a moderate level of disability (NIHSS score of 8 or more).
- You must be able to get a clot-busting medicine within 4.5 hours of stroke symptoms starting.
- You must be between 19 and 85 years old.
- Before this stroke, you could do all your usual activities without help (modified Rankin Scale 0 or 1).
- You must be willing and able to have brain MRI scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication (bevifibatide) to see which dose works best for people having an ischemic stroke who cannot get standard treatments like clot-busting drugs or a procedure to remove the clot. It aims to improve recovery by stopping clots from getting worse.
This trial tests a new approach for treating acute ischemic stroke within 4.5 hours of symptoms starting. It combines a special mobile stroke unit that delivers early brain-protecting medicine with standard clot-busting or clot-removal procedures, to see if this can improve recovery.
This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.
This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.
This trial tests a single dose of a new clot-dissolving medicine for people who had a stroke 4.5 to 24 hours ago. It may help if you cannot have standard treatments like a clot-removal procedure or other clot-busting drugs.
This trial tests a specialized clot-removal treatment for people who had a mild but disabling stroke up to 24 hours ago and have a large artery blockage in the brain. The goal is to see if this precision therapy can help reduce disability and improve recovery.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.